DNA damage response at telomeres boosts the transcription of SARS-CoV-2 receptor ACE2 during aging.


Journal

EMBO reports
ISSN: 1469-3178
Titre abrégé: EMBO Rep
Pays: England
ID NLM: 100963049

Informations de publication

Date de publication:
03 02 2022
Historique:
revised: 11 11 2021
received: 21 07 2021
accepted: 15 11 2021
pubmed: 3 12 2021
medline: 8 2 2022
entrez: 2 12 2021
Statut: ppublish

Résumé

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease 2019 (COVID-19), known to be more common in the elderly, who also show more severe symptoms and are at higher risk of hospitalization and death. Here, we show that the expression of the angiotensin converting enzyme 2 (ACE2), the SARS-CoV-2 cell receptor, increases during aging in mouse and human lungs. ACE2 expression increases upon telomere shortening or dysfunction in both cultured mammalian cells and in vivo in mice. This increase is controlled at the transcriptional level, and Ace2 promoter activity is DNA damage response (DDR)-dependent. Both pharmacological global DDR inhibition of ATM kinase activity and selective telomeric DDR inhibition by the use of antisense oligonucleotides prevent Ace2 upregulation following telomere damage in cultured cells and in mice. We propose that during aging telomere dysfunction due to telomeric shortening or damage triggers DDR activation and this causes the upregulation of ACE2, the SARS-CoV-2 cell receptor, thus contributing to make the elderly more susceptible to the infection.

Identifiants

pubmed: 34854526
doi: 10.15252/embr.202153658
pmc: PMC8811650
doi:

Substances chimiques

ACE2 protein, human EC 3.4.17.23
Angiotensin-Converting Enzyme 2 EC 3.4.17.23

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e53658

Subventions

Organisme : Fondazione Umberto Veronesi (Umberto Veronesi Foundation)
Organisme : EC|H2020|H2020 Priority Excellent Science|H2020 European Research Council (ERC)
ID : 835103
Organisme : EC|H2020|H2020 Priority Excellent Science|H2020 European Research Council (ERC)
ID : 875139
Organisme : Associazione Italiana per la Ricerca sul Cancro (AIRC)
ID : 21091
Organisme : NCI NIH HHS
ID : P50 CA070907
Pays : United States
Organisme : Fondazione Italiana di Ricerca per la Sclerosi Laterale Amiotrofica (AriSLA)
Organisme : Fondazione Telethon (Telethon Foundation)
ID : GGP17111
Organisme : Associazione Italiana per la Ricerca sul Cancro (AIRC)
ID : 21762

Informations de copyright

© 2021 The Authors. Published under the terms of the CC BY NC ND 4.0 license.

Références

Mol Cell. 2004 May 21;14(4):501-13
pubmed: 15149599
Nat Cell Biol. 2012 Mar 18;14(4):355-65
pubmed: 22426077
Life Sci. 2006 Apr 4;78(19):2166-71
pubmed: 16303146
FASEB J. 2020 Jun;34(6):7247-7252
pubmed: 32427393
Mech Ageing Dev. 2019 Jan;177:37-45
pubmed: 29604323
Annu Rev Genet. 2008;42:301-34
pubmed: 18680434
EMBO J. 2016 Jan 4;35(1):6-23
pubmed: 26628622
Nature. 2012 Aug 9;488(7410):231-5
pubmed: 22722852
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Cell. 2020 May 14;181(4):905-913.e7
pubmed: 32333836
Front Genet. 2021 Jan 21;11:630186
pubmed: 33552142
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Nucleic Acids Res. 2014 Jul;42(13):e104
pubmed: 24861623
Am J Respir Crit Care Med. 2020 Sep 1;202(5):756-759
pubmed: 32663409
J Cell Biol. 2020 Oct 5;219(10):
pubmed: 32777016
Nat Cell Biol. 2005 Jul;7(7):712-8
pubmed: 15968270
JAMA. 2020 Jun 16;323(23):2427-2429
pubmed: 32432657
Nat Commun. 2013;4:2848
pubmed: 24270157
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Nat Commun. 2019 Nov 18;10(1):4990
pubmed: 31740672
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Sci Rep. 2020 Dec 28;10(1):22401
pubmed: 33372179
Am J Physiol Lung Cell Mol Physiol. 2018 Aug 1;315(2):L313-L327
pubmed: 29722564
Front Oncol. 2015 Feb 03;5:11
pubmed: 25692096
Biomed Pharmacother. 2017 Oct;94:317-325
pubmed: 28772209
Genes Dev. 2011 Mar 1;25(5):409-33
pubmed: 21363960
Cell. 2020 May 28;181(5):1016-1035.e19
pubmed: 32413319
Nat Rev Drug Discov. 2021 Jun;20(6):427-453
pubmed: 33762737
Cell. 2021 Jan 21;184(2):306-322
pubmed: 33450206
Nature. 2013 Feb 28;494(7438):502-5
pubmed: 23389450
Aging Cell. 2020 Jul;19(7):
pubmed: 32558150
Cell. 2021 Jun 24;184(13):3573-3587.e29
pubmed: 34062119
J Cancer Metastasis Treat. 2017;3:45-59
pubmed: 28626800
Am J Physiol Lung Cell Mol Physiol. 2020 Jul 1;319(1):L39-L44
pubmed: 32491949
Lancet Infect Dis. 2020 Jun;20(6):669-677
pubmed: 32240634
J Biol Chem. 2000 Jun 30;275(26):19719-22
pubmed: 10787419
Nature. 2020 Jul;583(7817):590-595
pubmed: 32669714
Nat Cell Biol. 2017 Dec;19(12):1400-1411
pubmed: 29180822
Nat Commun. 2012 Feb 28;3:708
pubmed: 22426229
EMBO Rep. 2022 Jan 5;23(1):e52702
pubmed: 34693625
Nat Cell Biol. 2019 Oct;21(10):1286-1299
pubmed: 31570834
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):905-919
pubmed: 33389262
BMC Bioinformatics. 2012 Jun 18;13:134
pubmed: 22708584
Proc Natl Acad Sci U S A. 2020 Dec 11;:
pubmed: 33310900
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W247-52
pubmed: 19487240
Cell. 1997 Oct 3;91(1):25-34
pubmed: 9335332
Nat Commun. 2017 Feb 27;8:13980
pubmed: 28239143
Eye (Lond). 2020 Jul;34(7):1212-1219
pubmed: 32382146
Science. 2020 Sep 11;369(6509):
pubmed: 32913074
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Science. 2020 Mar 27;367(6485):1444-1448
pubmed: 32132184
EMBO J. 2020 May 18;39(10):e105114
pubmed: 32246845
Nat Commun. 2017 Nov 7;8(1):1356
pubmed: 29116081
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Aging Cell. 2016 Jun;15(3):446-54
pubmed: 26968134
Photochem Photobiol Sci. 2018 Dec 5;17(12):1842-1852
pubmed: 30065996
Cell. 1999 Mar 5;96(5):701-12
pubmed: 10089885
J Pathol. 2007 May;212(1):1-11
pubmed: 17464936
Nat Genet. 2021 Feb;53(2):205-214
pubmed: 33432184
Nature. 2020 May;581(7807):215-220
pubmed: 32225176
DNA Repair (Amst). 2017 Mar;51:14-19
pubmed: 28108274
Nature. 2003 Nov 13;426(6963):194-8
pubmed: 14608368
Nature. 1998 Apr 9;392(6676):569-74
pubmed: 9560153
Nature. 1990 May 31;345(6274):458-60
pubmed: 2342578

Auteurs

Sara Sepe (S)

IFOM Foundation-FIRC Institute of Molecular Oncology Foundation, Milan, Italy.

Francesca Rossiello (F)

IFOM Foundation-FIRC Institute of Molecular Oncology Foundation, Milan, Italy.

Valeria Cancila (V)

Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy.

Fabio Iannelli (F)

IFOM Foundation-FIRC Institute of Molecular Oncology Foundation, Milan, Italy.

Valentina Matti (V)

IFOM Foundation-FIRC Institute of Molecular Oncology Foundation, Milan, Italy.

Giada Cicio (G)

IFOM Foundation-FIRC Institute of Molecular Oncology Foundation, Milan, Italy.
Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy.

Matteo Cabrini (M)

IFOM Foundation-FIRC Institute of Molecular Oncology Foundation, Milan, Italy.
Istituto di Genetica Molecolare, Consiglio Nazionale delle Ricerche (IGM-CNR), Pavia, Italy.

Eugenia Marinelli (E)

IFOM Foundation-FIRC Institute of Molecular Oncology Foundation, Milan, Italy.
Istituto di Genetica Molecolare, Consiglio Nazionale delle Ricerche (IGM-CNR), Pavia, Italy.

Busola R Alabi (BR)

Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Alessia di Lillo (A)

IFOM Foundation-FIRC Institute of Molecular Oncology Foundation, Milan, Italy.

Arianna Di Napoli (A)

Department of Clinical and Molecular Medicine, Pathology Unit, Sant'Andrea Hospital, Sapienza University, Rome, Italy.

Jerry W Shay (JW)

Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Claudio Tripodo (C)

Tumor Immunology Unit, Department of Health Sciences, University of Palermo, Palermo, Italy.

Fabrizio d'Adda di Fagagna (F)

IFOM Foundation-FIRC Institute of Molecular Oncology Foundation, Milan, Italy.
Istituto di Genetica Molecolare, Consiglio Nazionale delle Ricerche (IGM-CNR), Pavia, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH